1.Date of occurrence of the event:2021/09/03
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter ”head office” or  ”subsidiaries”):head office

4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:Fespixon (research code: ON101) has demonstrated clinical superiority in the healing of the diabetic foot ulcers in the Phase 3 international multicenter clinical trial. The clinical data and its unique mechanism of action have been submitted to the JAMA Network Open, a medical journal published by the American Medical Association, and has been accepted for publication on September 3rd 2021.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)The American Medical Association is one of the top three global medical associations. The journal of the American Medical Association is also one of the internationally well-known journals. The JAMA Network Open is a leading journal of the general medicines and is an open access version published by the JAMA. It provides the research articles globally via online open access. Its impact factor is one of the highest among the general medicine open access journals according to the Science Citation Index (SCI). The journal’s websites attracts over 8.4 million annual visits and over 15.6 million article views and downloads which is academically influential and highly accessible.
(2)The publication of Fespixon’s Phase 3 data and mechanism of action is an acknowledgement by the JAMA Network Open on its clinical and scientific evidence. The open access online will increase the understanding of Fespixon’s efficacy by the international diabetic foot ulcer (DFU) specialists and also raise the global profile of the new drug. It is hoped that this will benefit the global DFU patients.
(3)The article is available online on JAMA Network Open:

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2783718?resultClick=1